Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Redhill Biopharma Ltd. (RDHL) vs China SXT Pharmaceuticals, Inc. (SXTC)

Redhill Biopharma Ltd. and China SXT Pharmaceuticals, Inc. are both Drug Manufacturers Specialty & Generic companies. Redhill Biopharma Ltd. and China SXT Pharmaceuticals, Inc. are of similar size ($3.5M and $3.2M). China SXT Pharmaceuticals, Inc. grew revenue faster over the last twelve months: −54.0% against −61.9%. Redhill Biopharma Ltd. has the higher net margin (25.2% vs −255.2%) and the higher return on invested capital (0.00% vs 0.00%). Across the 11 metrics below, China SXT Pharmaceuticals, Inc. leads on 7 and Redhill Biopharma Ltd. on 4.

Valuation

Metric RDHL SXTC Drug Manufacturers Specialty & Generic median
P/E n/m n/m 20.14
P/S 0.32 n/m 2.25
P/B n/m n/m 1.90
Price to free cash flow n/m n/m 16.54
EV/EBITDA n/m 2.66 12.29
EV/Sales 0.30 (5.94) 2.56
Earnings yield (122,133.34%) (4,331.13%) (2.99%)
Free cash flow yield (909.75%) 0.00% 0.00%

Profitability

Metric RDHL SXTC Drug Manufacturers Specialty & Generic median
Gross margin 35.16% 36.69% 53.94%
Operating margin 0.00% 0.00% 0.00%
Net margin 25.20% (255.16%) 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 0.00% 0.00% (0.40%)
Return on assets 0.00% 0.00% (3.32%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric RDHL SXTC Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) (61.93%) (53.98%) 10.01%
EPS growth (last fiscal year) 97.91% 97.36% —
Revenue growth, 5-year CAGR (66.15%) (24.94%) 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric RDHL SXTC Drug Manufacturers Specialty & Generic median
Debt to equity 0.00 0.03 0.05
Current ratio 0.56 7.94 2.31
Net debt to EBITDA 0.53 3.86 0.85

Dividend

Metric RDHL SXTC Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric RDHL SXTC Drug Manufacturers Specialty & Generic median
Market cap 3.22m 3.49m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack